Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

Luca Gianni; José Baselga; Wolfgang Eiermann; Vicente Guillem Porta; Vladimir Semiglazov; Aña Lluch; Milvia Zambetti; Dolores Sabadell; Günther Raab; Antonio Llombart Cussac; Alla Bozhok; Angel Martinez-Agulló; Marco Greco; Mikhail Byakhov; Juan Josè Lopez Lopez; Mauro Mansutti; Pinuccia Valagussa; Gianni Bonadonna

doi:10.1158/1078-0432.CCR-05-0539

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

Luca Gianni, José Baselga, Wolfgang Eiermann, Vicente Guillem Porta, Vladimir Semiglazov, Aña Lluch, Milvia Zambetti, Dolores Sabadell, Günther Raab, Antonio Llombart Cussac, Alla Bozhok, Angel Martinez-Agulló, Marco Greco, Mikhail Byakhov, Juan Josè Lopez Lopez, Mauro Mansutti, Pinuccia Valagussa, Gianni Bonadonna

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Institute toxicities were low (

Original language	English
Pages (from-to)	8715-8721
Number of pages	7
Journal	Clinical Cancer Research
Volume	11
Issue number	24
DOIs	https://doi.org/10.1158/1078-0432.CCR-05-0539
Publication status	Published - Dec 15 2005

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1158/1078-0432.CCR-05-0539

Fingerprint Dive into the research topics of 'Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy'. Together they form a unique fingerprint.

Cite this

Gianni, L., Baselga, J., Eiermann, W., Porta, V. G., Semiglazov, V., Lluch, A., Zambetti, M., Sabadell, D., Raab, G., Cussac, A. L., Bozhok, A., Martinez-Agulló, A., Greco, M., Byakhov, M., Lopez Lopez, J. J., Mansutti, M., Valagussa, P., & Bonadonna, G. (2005). Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research, 11(24), 8715-8721. https://doi.org/10.1158/1078-0432.CCR-05-0539

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. / Gianni, Luca; Baselga, José; Eiermann, Wolfgang; Porta, Vicente Guillem; Semiglazov, Vladimir; Lluch, Aña; Zambetti, Milvia; Sabadell, Dolores; Raab, Günther; Cussac, Antonio Llombart; Bozhok, Alla; Martinez-Agulló, Angel; Greco, Marco; Byakhov, Mikhail; Lopez Lopez, Juan Josè; Mansutti, Mauro; Valagussa, Pinuccia; Bonadonna, Gianni.

In: Clinical Cancer Research, Vol. 11, No. 24, 15.12.2005, p. 8715-8721.

Research output: Contribution to journal › Article

Gianni, L, Baselga, J, Eiermann, W, Porta, VG, Semiglazov, V, Lluch, A, Zambetti, M, Sabadell, D, Raab, G, Cussac, AL, Bozhok, A, Martinez-Agulló, A, Greco, M, Byakhov, M, Lopez Lopez, JJ, Mansutti, M, Valagussa, P & Bonadonna, G 2005, 'Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy', Clinical Cancer Research, vol. 11, no. 24, pp. 8715-8721. https://doi.org/10.1158/1078-0432.CCR-05-0539

Gianni, Luca ; Baselga, José ; Eiermann, Wolfgang ; Porta, Vicente Guillem ; Semiglazov, Vladimir ; Lluch, Aña ; Zambetti, Milvia ; Sabadell, Dolores ; Raab, Günther ; Cussac, Antonio Llombart ; Bozhok, Alla ; Martinez-Agulló, Angel ; Greco, Marco ; Byakhov, Mikhail ; Lopez Lopez, Juan Josè ; Mansutti, Mauro ; Valagussa, Pinuccia ; Bonadonna, Gianni. / Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 24. pp. 8715-8721.

@article{4da3d8847fb34b68b9e5062aef42f0e0,

title = "Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy",

abstract = "Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Institute toxicities were low (",

author = "Luca Gianni and Jos{\'e} Baselga and Wolfgang Eiermann and Porta, {Vicente Guillem} and Vladimir Semiglazov and A{\~n}a Lluch and Milvia Zambetti and Dolores Sabadell and G{\"u}nther Raab and Cussac, {Antonio Llombart} and Alla Bozhok and Angel Martinez-Agull{\'o} and Marco Greco and Mikhail Byakhov and {Lopez Lopez}, {Juan Jos{\`e}} and Mauro Mansutti and Pinuccia Valagussa and Gianni Bonadonna",

year = "2005",

month = dec,

day = "15",

doi = "10.1158/1078-0432.CCR-05-0539",

language = "English",

volume = "11",

pages = "8715--8721",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "24",

}

TY - JOUR

T1 - Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

AU - Gianni, Luca

AU - Baselga, José

AU - Eiermann, Wolfgang

AU - Porta, Vicente Guillem

AU - Semiglazov, Vladimir

AU - Lluch, Aña

AU - Zambetti, Milvia

AU - Sabadell, Dolores

AU - Raab, Günther

AU - Cussac, Antonio Llombart

AU - Bozhok, Alla

AU - Martinez-Agulló, Angel

AU - Greco, Marco

AU - Byakhov, Mikhail

AU - Lopez Lopez, Juan Josè

AU - Mansutti, Mauro

AU - Valagussa, Pinuccia

AU - Bonadonna, Gianni

PY - 2005/12/15

Y1 - 2005/12/15

N2 - Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Institute toxicities were low (

AB - Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Institute toxicities were low (

UR - http://www.scopus.com/inward/record.url?scp=29344467956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344467956&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0539

DO - 10.1158/1078-0432.CCR-05-0539

M3 - Article

C2 - 16361558

AN - SCOPUS:29344467956

VL - 11

SP - 8715

EP - 8721

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -